drugset / Trial / NCT00426946

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

NCT00426946

Phase 4 Unknown 60 enrolled Geha Mental Health Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the present study is to prospectively assess the anti-depressant effectiveness of reboxetine in children and adolescents, as compared with fluoxetine, in a randomized controlled open-label trial.

Timeline

Start
2005-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Reboxetine Unknown 4 mg
Subject Reboxetine Unknown 8 mg

Indications